Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 60,800
-2,600 (-4.10%)
At close: Apr 9, 2026
Next Biomedical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 |
Depreciation & Amortization | 518.51 | 492.36 | 467.32 | 463.41 | 433.53 |
Loss (Gain) From Sale of Assets | -9.81 | -4.24 | - | -5.29 | -69.58 |
Asset Writedown & Restructuring Costs | - | - | - | 38.72 | 0.8 |
Loss (Gain) From Sale of Investments | 77.07 | -113.58 | -133.56 | 102.48 | 65.86 |
Stock-Based Compensation | 1,188 | 2,107 | 1,486 | 310.27 | 324.19 |
Other Operating Activities | 350.13 | -6,005 | 2,492 | -924.41 | 10,046 |
Change in Accounts Receivable | -430.04 | -876.88 | -617.38 | -199.44 | -14.62 |
Change in Inventory | -426.83 | -366.66 | -228.8 | -626.88 | 660.13 |
Change in Accounts Payable | 34.32 | -44.78 | 13.14 | 40.91 | -5.08 |
Change in Other Net Operating Assets | 260.33 | 752.12 | -117.41 | -1,676 | -192.62 |
Operating Cash Flow | 1,250 | -1,201 | -4,160 | -8,208 | -5,396 |
Capital Expenditures | -3,152 | -439.39 | -64.54 | -195.07 | -704.65 |
Sale of Property, Plant & Equipment | 21.31 | 4.27 | - | 19.47 | 380 |
Sale (Purchase) of Intangibles | - | - | - | - | -69.59 |
Investment in Securities | 5,242 | -25,626 | 4,171 | -10,785 | -714.73 |
Other Investing Activities | -427.32 | -299.43 | 0.01 | 16.16 | 13.72 |
Investing Cash Flow | 1,684 | -26,361 | 4,106 | -10,945 | -1,095 |
Short-Term Debt Issued | - | - | - | - | 2,400 |
Long-Term Debt Issued | 1,080 | 369 | 931 | 500 | - |
Total Debt Issued | 1,080 | 369 | 931 | 500 | 2,400 |
Short-Term Debt Repaid | -3,440 | - | - | - | -1,230 |
Long-Term Debt Repaid | -971.14 | -939.53 | -441.66 | -451.4 | -439.48 |
Total Debt Repaid | -4,411 | -939.53 | -441.66 | -451.4 | -1,669 |
Net Debt Issued (Repaid) | -3,331 | -570.53 | 489.34 | 48.6 | 730.52 |
Issuance of Common Stock | 2,236 | 28,920 | 484.29 | 46.56 | - |
Other Financing Activities | - | -0 | -0 | -0 | -0 |
Financing Cash Flow | -1,095 | 28,349 | 973.63 | 95.17 | 21,728 |
Foreign Exchange Rate Adjustments | -0.35 | 260.79 | -31.74 | 55.26 | 39.87 |
Net Cash Flow | 1,839 | 1,048 | 888.07 | -19,002 | 15,276 |
Free Cash Flow | -1,902 | -1,640 | -4,225 | -8,403 | -6,101 |
Free Cash Flow Margin | -11.54% | -17.18% | -86.53% | -300.65% | -269.08% |
Free Cash Flow Per Share | -232.28 | -227.68 | -672.87 | -1353.18 | -1260.87 |
Cash Interest Paid | 486.43 | 524.36 | 572.14 | 354.01 | 241.79 |
Cash Income Tax Paid | - | - | 63.92 | -1.76 | 15.73 |
Levered Free Cash Flow | -4,293 | -3,155 | -3,756 | -6,103 | -31,008 |
Unlevered Free Cash Flow | -4,063 | -2,830 | -3,397 | -5,877 | -30,125 |
Change in Working Capital | -562.22 | -536.21 | -950.45 | -2,462 | 447.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.